Increased mortality in schizophrenia and the possible influence of antipsychotic treatment

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 2, 1998, Pages

  Bandelow, Borwin ^a   Fritze, Jürgen ^b   Rüther, Eckart ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

Antipsychotic drugs; QT prolongation; Schizophrenia; Sudden death; Torsade de pointes

Indexed keywords

AMANTADINE; AMISULPRIDE; BROMOCRIPTINE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLONAZEPAM; DANTROLENE; DROPERIDOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; PIMOZIDE; RISPERIDONE; SERTINDOLE; SULTOPRIDE; THIORIDAZINE; VALPROIC ACID;

AGRANULOCYTOSIS; CATATONIA; DOSE CALCULATION; DRUG SAFETY; HEART ARREST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; LONG QT SYNDROME; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; SUBSTANCE ABUSE; SUDDEN DEATH; SUICIDAL BEHAVIOR; VIOLENCE;

EID: 0032410395     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Gausset MF, Casadebaig F, Guillaud Bataille JM et al (1992) Mortality of mentally ill patients. Review of the literature [French]. Encéphale 18: 93-100.
2. Bruce ML, Leaf PJ, Rozal GP et al (1994) Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psychiatry 151: 716-21.
3. Lesage AD, Trapani V, Tansella M (1990) Excess mortality by natural causes of Italian schizophrenic patients. Eur Arch Psychiatry Neurol Sci 239: 361-5.
4. Newman SC, Bland RC (1991) Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36: 239-45.
5. Saku M, Tokudome S, Ikeda M et al (1995) Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. Int J Epidemiol 24: 366-72.
6. Simpson JC, Tsuang MT (1996) Mortality among patients with schizophrenia. Schizophr Bull 22: 485-99.
7. Black DW, Fisher R (1992) Mortality in DSM-III-R schizophrenia. Schizophr Res 2: 109-16.
8. Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders. Br J Psychiatry 170: 205-28.
9. Bandelow B, Müller P, Gaebel W et al (1990) Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich. Eur Arch Psychiatry Clin Neurosci 240: 113-20.
10. Bandelow B, Müller P, Frick U et al (1992) Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci 241: 291-5.
11. Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8: 671-7.
12. Mortensen PB, Juel K (1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163: 183-9.
13. Tsuang MT, Woolson RF (1978) Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess? Arch Gen Psychiatry 35: 1181-5.
14. Black DW, Winokur G (1988) Age, mortality and chronic schizophrenia. Schizophr Res 1: 267-72.
15. Tabbane K, Joober R, Spadone C et al (1993) Mortality and cause of death in schizophrenia. Review of the literature [French]. Encéphale 19: 23-8.
16. Allebeck P (1989) Schizophrenia: a life-shortening disease. Schizophr Bull 15: 81-9.
17. Allebeck P, Varla A, Wistedt B (1986) Suicide and violent death among patients with schizophrenia. Acta Psychiatr Scand 74: 43-9.
18. Mortensen PB, Juel K (1990) Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 81: 372-7.
19. Tsuang MT, Woolson RF, Fleming JA (1980) Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 37: 979-83.
20. Smith J, Hucker S (1994) Schizophrenia and substance abuse. Br J Psychiatry 165: 13-21.
21. Bell LV (1849) On a form of disease resembling mania and fever. Am J Insanity 6: 97-127.
22. Peele R, Von Loetzen IS (1973) Phenothiazine deaths: a critical review. Am J Psychiatry 130: 306-9.
23. Singerman B, Raheja R (1994) Malignant catatonia - a continuing reality. Ann Clin Psychiatry 6: 259-66.
24. Jeste DV, Gladsjo JA, Lindamer LA et al (1996) Medical comorbidity in schizophrenia. Schizophr Bull 22: 413-30.
25. Ziedonis DM, George TP (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23: 247-54.
26. Hambrecht M, Hafner H (1996) Substance abuse and the onset of schizophrenia. Biol Psychiatry 40: 1155-63.
27. Moen A, Sorheim S, Brun H et al (1992) Dodsfall forarsaket av antidepressiva og neuroleptika. Risikogrupper belyst ved et rettsmedisinsk materiale. Tidsskr Nor Laegeforen 112: 612-5.
28. Dalmau A, Bergman B, Brismar B (1997) Somatic morbidity in schizophrenia - a case control study. Public Health 111: 393-7.
29. Zaccara G, Muscas GC, Messori A (1990) Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf 5: 109-51.
30. Toth P, Frankenburg FR (1994) Clozapine and seizures: a review. Can J Psychiatry 39: 236-8.
31. Buckley NA, Whyte IM, Dawson AH (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33: 199-204.
32. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41: 369-71.
33. Thomas SHL, Higham PD, Hartigan-Go K et al (1995) Concentration-dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74: 53-6.
34. Van de Loo A, Klingenheben T, Hohnloser SH (1994) Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects [German]. Z Kardiol 83: 887-90.
35. Fritze J, Bandelow B (1998) QT interval prolongation and the atypical antipsychotic sertindole. Int J Psychiatry Clin Pract 2: 'in press'.
36. Mueller CE, Frost GL, Elenbaas RM (1983) Haloperidol-overdose-induced torsade de pointes. Drug Intell Clin Pharm 17: 440.
37. Zee-Cheng CS, Mueller CE, Seifert CF, Gibbs HR (1985) Haloperidol and torsade de pointes. Ann Intern Med 102: 418.
38. Turbott J, Cairns FJ. (1984) Sudden death and neuroleptic medication. Am J Psychiat 141: 919-20.
39. Aunsholt NA (1989) Prolonged Q-T interval and hypokalemia caused by haloperidol. Acta Psychiatr Scand 79: 411-12.
40. Guy JM, André-Fouet X, Port J et al (1991) Torsade de pointes et allongement de la durée de l'intervalle QT après injection de dropéridol. Ann Cardiol Angéiol 40: 541-45.
41. Lawrence KR, Nasraway SQ (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531-7.
42. Harry P (1997) Acute poisoning by new psychotropic drugs. [French]. Rev Prat 47: 731-5.
43. Tracqui A, Mutter Schmidt C, Kintz P et al (1995) Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 14: 294-8.
44. Faigel DO, Metz DC, Kochman ML (1995) Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol 90: 822-4.
45. Metzger E, Friedman R (1993) Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 13: 128-32.
46. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154: 782-91.
47. Barnett AA (1996) Safety concerns over antipsychotic drug, sertindole. Lancet (348) (July 27): 256.
48. Bandelow B, Degner D, Kreusch U, Rüther E (1995) Myocarditis under therapy with clozapine. Schizophr Res 17: 293-4.
49. Jensen VE, Gotzsche O (1994) Allergisk myocarditis ved klozapinbehandling. Ugeskr Laeger 156 (28): 4151-2.
50. Meeker JE, Herrmann PW, Som CW, Reÿnolds PC (1992) Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 16: 54-6.
51. Clinton JE, Sterner S, Stelmachers Z, Ruiz E (1987) Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 16: 319-22.
52. Dudley DL, Rowlett DB, Loebel PJ (1979) Emergency use of intravenous haloperidol. Gen Hosp Psychiatry 1: 240-6.
53. Oldham AJ, Bott M (1971) The management of excitement in a general hospital psychiatric ward by high dosage haloperidol. Acta Psychiatr Scand 47: 369-76.
54. Alvir JM, Lieberman JA (1994) Agranulocytosis: incidence and risk factors. J Clin Psychiatry 55(suppl B): 137-8.
55. Pisciotta AV (1969) Agranulocytosis induced by certain phenothiazine derivatives. JAMA 208: 1862-8.
56. Grohmann R, Rüther E (1994) Neuroleptika In: Unerwünschte Wirkungen von Psychopharmaka. (eds R Grohmann, E Rüther, LG Schmidt), 42-133. Springer, Berlin.
57. Caroff SN (1980) The neuroleptic malignant syndrome. J Clin Psychiatry 41: 79-83.
58. Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77: 185-202.
59. Martin TG (1996) Serotonin syndrome. Ann Emerg Med 28: 520-6.
60. Coffey CE, Ross DR (1980) Treatment of lithium/neuroleptic neurotoxicity during lithium maintenance. Am J Psychiatry 137: 736-7.
61. Spiess-Kiefer C, Hippius H (1986) Malignes Neuroleptisches Syndrom und maligne Hyperthermie: ein Vergleich. Fortschr Neurol Psychiatr 54: 158-70.
62. König F, Loble M, Wolfersdorf M (1996) Depressive stupor-malignant neuroleptic syndrome-serotonin syndrome. A case contribution to a difficult differential diagnosis [German]. Nervenarzt 67: 407-12.
63. Chatterton R, Cardy S, Schramm TM (1996) Neuroleptic malignant syndrome and clozapine monotherapy. Aust N Z J Psychiatry 30: 692-3.
64. Meterissian GB (1996) Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 41: 52-4.
65. Sharma R, Trappler B, Ng YK, Leeman CP (1996) Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 30: 775-8.
66. Young DM (1996) Risk factors for hypothermia in psychiatric patients. Ann Clin Psychiatry 8: 93-7.
67. Grohmann R, Rüther E, Sassim N, Schmidt LG (1989) Adverse effects of clozapine. Psychopharmacology Berlin 99(suppl): S101-4.
68. Leestma JE, Koenig KL (1968) Sudden death and phenothiazines. Arch Gen Psychiatry 18: 137-48.
69. Modestin J, Krapf R, Böker W (1983) A fatality during haloperidol treatment: mechanism of sudden death. Am J Psychiatry 138: 1616-7.
70. Ungvári G (1980) Neuroleptic-related sudden death (proven or a mere hypothesis?). Pharmakopsychiatr Neuropsychopharmakol 13: 29-33.
71. Ungvári G (1985) Sudden cardiac deaths among psychiatric patients receiving neuroleptics. Acta Méd Leg Soc Liège 35: 268-70.
72. Jusic N, Lader M (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 165: 787-91.
73. Flaherty JA, Lahmeyer HW (1978) Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 135: 1414-5.
74. Leestma JE, Annegers JF, Brodie MJ et al (1997) Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 38: 47-55.
75. Risch SC, Groom GP, Janowsky DS (1982) The effects of psychotropic drugs on the cardiovascular system. J Clin Psychiatry 43: 16-31.
76. Settle EC, Ayd FJ (1983) Haloperidol: a quarter century of experience. J Clin Psychiatry 44: 440-8.
77. Simpson GM, Davis J, Jefferson JW (1987) Sudden deaths in psychiatric patients: the role of neuroleptic drugs. American Psychiatric Association Task Force Report 27. APA, Washington, DC.
78. Royal College of Psychiatrists (1997) The association between antipsychotic drugs and sudden death. Report of the Work Group of The Royal College of Psychiatrists' Psychopharmacology Sub-Group Council Report CR 57. ACP, London.
79. Davies MJ (1992) Unexplained death in fit young people. Br Med J 305: 538-9.
80. Gullestad L, Kjekshus J (1992) Plutselig hjertedod. Betydning av betablokkere. Tidsskr Nor Laegeforen 112: 2843-7.
81. Kannel WB, Doyle JT, McNamara PM et al (1975) Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 51: 606-13.
82. Committee on Safety of Medicines (1996) Drug-induced prolongation of the QT interval. Curr Probl Pharmacovigilance 22:2.
83. Bandelow B (1998) Neuroleptika. In: Handbuch der Arzneimitteltherapie. Band 1: Psychopharmaka, (eds J Fox, E Rüther), 65-114.